VIDEO: Utilizing minimal residual disease testing in acute lymphoblastic leukemia
Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute lymphoblastic leukemia presented at Society of Hematologic Oncology Annual Meeting.
“There was very good discussion initially on [minimal residual disease (MRD)] testing in ALL,” Molina, associate staff clinician in the leukemia and myeloid disorders division at Cleveland Clinic, told Healio. “With a real push, that next-generation sequencing that provides a much deeper disease assessment is planning to be the superior method to assess disease.”
He added that “it’s deeper, has better prediction of leukemia-free survival, better prediction pre-transplant in terms of relapse and overall survival. It’s superior to flow cytometry in the post-transplant setting as well.”
Collapse
Healio Interviews
Read more about